Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
Why is this work in the frame?
A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.
Abstract
BACKGROUND: Lu)-PSMA-617 is a radioligand therapy that delivers beta-particle radiation to PSMA-expressing cells and the surrounding microenvironment. METHODS: Ra), and investigational drugs. The alternate primary end points were imaging-based progression-free survival and overall survival, which were powered for hazard ratios of 0.67 and 0.73, respectively. Key secondary end points were objective response, disease control, and time to symptomatic skeletal events. Adverse events during treatment were those occurring no more than 30 days after the last dose and before subsequent anticancer treatment. RESULTS: Lu-PSMA-617 than without (52.7% vs. 38.0%), but quality of life was not adversely affected. CONCLUSIONS: Lu-PSMA-617 prolonged imaging-based progression-free survival and overall survival when added to standard care in patients with advanced PSMA-positive metastatic castration-resistant prostate cancer. (Funded by Endocyte, a Novartis company; VISION ClinicalTrials.gov number, NCT03511664.).
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
The record
- Venue
- New England Journal of Medicine
- Topic
- Prostate Cancer Treatment and Research
- Field
- Medicine
- Canadian institutions
- BC Cancer Agency
- Funders
- National Cancer InstituteNational Institute for Health and Care ResearchAdvanced Accelerator ApplicationsEndocyteNovartis
- Keywords
- Prostate cancerMedicineCastrationOncologyCancer researchProstateInternal medicineCancerHormone
- Has abstract in OpenAlex
- yes